All In Biotech

Drug Trial Radar · NCT05514340

Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase-II Trial to Assess Safety, and Efficacy of Sovateltide in the Treatment of Hypoxic-ischemic Encephalopathy in Neonates

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 6, 2023

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition. Sovateltide augments neuronal progenitor cell differentiation and better mitochondrial morphology and biogenesis to activate a regenerative response in the central nervous system. The only treatment for HIE is therapeutic hypothermia with limited success, and studies indicate that sovateltide may be beneficial in these patients.

Conditions

  • Hypoxic-Ischemic Encephalopathy
  • Neonatal Asphyxia
  • Neonatal Encephalopathy

Interventions

  • Normal Saline along with standard treatmentDrug

    Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.

  • Sovateltide along with standard treatmentDrug

    Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with death or disability (moderate/severe)Time frame: 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Father Muller Medical College Hospital

    Mangalore, Karnataka, India · Recruiting

  • Christian Medical College and Hospital

    Ludhiana, Punjab, India · Recruiting

  • Niloufer Hospital

    Hyderabad, Telangana, India · Not yet recruiting

  • GSVM Medical College

    Kanpur, Uttar Pradesh, India · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.